Effect of BD Regimen Combined with Cyclophosphamide and Pirarubicin in Treatment of Relapse/Refractory Multiple Myeloma

• Published in: Zhongguo shi yan xue ye xue za zhi Vol. 24; no. 5; p. 1454
• Main Authors: Wang, Yu-Fen, Xu, Wen-Jun, Chen, Yu-Li, Ma, Xiao-Huan, Qiu, Zhi-Yuan, Ren, Cui-Ai
• Format: Journal Article
• Language: Chinese
• Published: China 01.10.2016
• Subjects: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin - analogs & derivatives; Humans; Lomustine; Multiple Myeloma; Neoplasm Recurrence, Local; Vindesine
• ISSN: 1009-2137
• DOI: 10.7534/j.issn.1009-2137.2016.05.031

To compare the efficacy and safety of BD regimen combined with cyclophosphamide(CTX) and pirarubicin chemotherapy(P-CAD) for patients with relapse/refractory multiple myeloma(MM). Twenty-eight cases of relapse/refractory MM were enrolled in a group of P-CAD regimen, 36 cases of relapse/retractory MM treated with BD were used as controls. The therapeutic efficacy and adverse reactions of 2 regimens for patients with relapse/retractory MM were compared and analyzed. The overall response rate (CR+NCR+PR+MR) of the 28 cases treated with P-CAD regimen was 85.7%, and the response rate (CR+PR) was 75.0%. The median progression-free survival time were 16.1 months, and the average survival time were 30.6 months, while the overall response rate of the 36 patients treated with BD regimen was 63.9%, and the response rate was 55.6%. The median progression-free survival time were 13.7 months, and the average survival time were 26.7 months. The adverse reactions of 2 groups included gastrointestinal reactions, peripheral ne